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Neutrophil in®ltration and epidermal hyperprolifera-
tion are major histopathologic changes observed in
psoriasis. Neutrophils contain human leukocyte elas-
tase, which is thought to be released during neutro-
phil in®ltration of the epidermis. As active human
leukocyte elastase is known to be present in psoriatic
lesions we were interested whether human leukocyte
elastase induces hyperproliferation in keratinocytes
in vitro and in vivo. In the cultured murine keratino-
cyte cell line PAM-212 concentrations of human leu-
kocyte elastase from 1 to 30 nM induced signi®cant
proliferation as determined by 5-bromo-2¢-deoxy-
uridine-incorporation. Daily topical application of
0.043±434.8 pmol human leukocyte elastase per cm2
skin on hairless mice induced a concentration-
dependent epidermal hyperproliferation and an
increase in 5-bromo-2¢-deoxy-uridine incorporation
of up to 5-fold in basal keratinocytes within 3 d.
Hyperproliferation resulted in a up to 2-fold increase
of keratinocyte layers. Histologic analysis revealed
marked vasodilatation but no in¯ammatory in®ltrate.
Application of porcine pancreatic elastase (3±
300 pmol per cm2 skin) resulted in similar epidermal
changes as observed for human leukocyte elastase.
Hyperproliferative effects of human leukocyte elas-
tase in vitro and in vivo were abolished by the add-
ition of elastase inhibitors, such as ela®n, anti-
leukoprotease, and a1-protease inhibitor. In sum-
mary, human leukocyte elastase induces proliferation
in murine keratinocytes in concentrations, which can
be found on the skin surface of psoriatic lesions.
These results may provide an explanation for the epi-
dermal hyperproliferation observed in psoriasis. Key
words: elastase/keratinocyte proliferation/psoriasis/serine
proteases. J Invest Dermatol 118:49±54, 2002
T
he traditional view that broad-spectrum serine
proteases are mainly degrading extracellular proteins
has changed dramatically with the discovery of
protease receptors that are activated by proteolysis.
Following proteolysis, a new N-terminus of the
extracellular position of the receptor occurs, which acts as a
tethered ligand. There are four known members of this receptor
family of protease-activated receptors (PAR): PAR-1, PAR-3, and
PAR-4, which are cleaved and activated by thrombin, and PAR-2,
a receptor for trypsin-like enzymes. Recent investigations indicate
that certain serine proteases are signaling molecules and regulate
multiple cellular functions by activating speci®c PAR. Agonists of
PAR-1 and PAR-2 stimulate mitogen-activated protein kinases
and may regulate cellular growth and proliferation (Belham et al,
1996; Yu et al, 1997); however, the effects of PAR-2 agonists on
growth depend on the cell type. Both PAR-2 and PAR-1 agonists
stimulate proliferation of endothelial cells and ®broblasts (Mirza et
al, 1996). In contrast, whereas PAR-1 agonists stimulate growth of
keratinocytes, PAR-2 agonists inhibit keratinocyte growth and
differentiation (Derian et al, 1997).
Human leukocyte elastase (HLE) is a broad-spectrum serine
protease (30 kDa) primarily located in the azurophil granules of
polymorphonuclear leukocytes in very high concentrations (2 pg
enzyme per cell) (Wiedow et al, 1996). Participation of elastase in
signaling processes has been shown in recent investigations. HLE
regulates the expression and secretion of its inhibitor ela®n in the
alveolar cell line A549 (Reid et al, 1999). Inhibition of HLE-
induced interleukin-8 gene expression by urinary trypsin inhibitor
has been demonstrated in human bronchial epithelial cells
(Nakamura et al, 1997); however, activation of speci®c PAR by
HLE has not been described yet.
Psoriasis is morphologically characterized by epidermal hyper-
proliferation and neutrophil in®ltrates in the epidermis. Active
HLE is detectable in psoriatic lesions and correlates with skin
induration (Wiedow et al, 1992) and disappears with successful
therapy of the disease (Wiedow et al, 1995). Knowing that other
serine proteases exhibit mitogen effects we were interested to
determine whether HLE is an important stimulus for keratinocyte
proliferation in vitro and in vivo.
MATERIALS AND METHODS
Materials HLE was obtained from Elastin Products (Paci®c, MO).
Active sites were titrated with recombinant eglin C (Ciba Geigy, Basel,
Switzerland). HLE proved to be more than 80% catalytically active. HLE
was dissolved in 0.1 M sodium acetate (pH 5.0) and diluted with
phosphate-buffered saline immediately before application.
Culture of murine keratinocytes The spontaneously transformed
murine keratinocyte cell line (PAM-212; American Type Culture
Collection, Rockville, MD) was cultured in RPMI-1640 medium
(Gibco BRL, Rockville, MD) supplemented with 5% fetal bovine serum
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and antibiotics (100 units penicillin per ml and 100 units streptomycin
per ml) and incubated at 37°C in 5% CO2 and humid atmosphere.
Keratinocyte proliferation assay Proliferation of cultured cells was
assessed by 5-bromo-2¢-deoxy-uridine (BrdU) labeling as described
previously (Porstmann et al, 1985). Keratinocytes were plated in 96-well
¯at-bottomed microtiter plates at a density of 3000 cells per well and
cultured overnight. Cells were washed twice with phosphate-buffered
saline and the medium was replaced with RPMI-1640 containing 1%
(wt/vol) bovine serum albumin (Sigma, St. Louis, MO) supplemented
with HLE in various concentrations, ela®n (100 nM), anti-leukoprotease
(or secretory leukocyte protease inhibitor; 100 nM) or recombinant
human epidermal growth factor (100 nM). The cells were then
incubated for 24 h in the presence of 100 mM BrdU. Incorporation of
BrdU was determined using a cell proliferating enzyme-linked
immunosorbent assay (Proliferation ELISA, Roche, Mannheim,
Germany) according to the manufacturer's instructions. The absorbance
was measured using a spectrophotometer at 450 nm vs 620 nm.
Absorbance was corrected to the measured absorbance of buffer control.
Mean values and standard deviations were calculated, and the signi®cance
level of given differences was determined with the c2-test. The index of
proliferation was calculated by dividing the average of the measured
absorbance after stimulation by the average of the absorbance of
untreated cells. Enzyme activity was con®rmed by substrate assay.
Animals Hairless male mice [strain SKH I (hr/hr) BR from Charles
River, Sulzfeld, Germany] 6±8 wk old and weighing 20±30 g were used.
All animals were housed in plastic cages and given food and water ad
libitum. The treatment was practiced under ether anesthesia. The study
was approved by the ethic committee of the Medical Faculty, University
of Kiel.
Transepidermal water loss (TEWL) The mice were treated with
acetone-soaked cotton balls on both ¯anks to remove the outer lipids of
the epidermis and in order to facilitate the penetration of proteins. The
TEWL was measured using an electrolytic water analyzer (MEECO,
Warrington, PE). Dry nitrogen was passed through a Te¯on tube to a
metal cup placed upon the skin. The nitrogen gas was moistened by
water vapor derived from perspiration at the skin surface and conducted
to the implement where the water was split up into oxygen and
hydrogen. An ampere meter registered the electric current resulting from
this electrolysis. The scale of the electrolytic water analyzer read ppm
water by volume (1 ppm = 0.25 g H2O per cm
2 skin surface per h).
The skin barrier was considered to be suf®ciently removed when the
TEWL reached a value of between 400 and 600 ppm. The regeneration
of the barrier was examined by measuring the TEWL after 0, 24, 48,
and 72 h. The mean values were calculated and the range was
determined. The data were recorded as a percentage of the reference
(= 100%) immediately after the removal of the skin barrier.
Application of enzymes After pretreatment with acetone a marked
area (1 cm2) was treated with enzyme solutions and control buffers. HLE
concentrations of 0.043±434.8 pmol per 10 ml (4.3 nM±43.48 mM) were
applied on 1 cm2 skin. Porcine pancreatic elastase (Mr 27,000, EC
3.4.21.36, Serva, Heidelberg, Germany) was active site titrated with
recombinant ela®n. It was dissolved in 0.1 M sodium acetate (pH 5.0)
and diluted with phosphate-buffered saline. Concentrations of 0.3±
300 pmol per 30 ml were applied. The sites of application were covered
with adherent aluminum chambers (Finn Chambers on Scanpor, Hermal,
Reinbek, Germany). Enzymes and controls were repeatedly applied
under occlusion after 0, 24, and 48 h. Furthermore, HLE (434.8 pmol
per cm2) was applied in comparison with complexes of HLE and its
physiologic inhibitors ela®n (recombinant human ela®n, ICI
Pharmaceuticals, Maccles®eld, U.K.), anti-leukoprotease (recombinant
human anti-leukoprotease, GruÈnenthal GmbH, Aachen, Germany) and
a1-proteinase inhibitor (Sigma, St. Louis, MO). A sample of enzyme was
titrated with each of the inhibitor until the methoxy-succinyl-alanyl-
alanyl-prolyl-valine-p-nitroanilide hydrolyzing activity was below 0.5%
of the enzyme solution. After 24, 48, and 72 h the erythema was
evaluated visually.
Histology The tissue was ®xed in formaldehyde and embedded in
paraf®n. Sections were stained with hematoxylin and eosin. The
epidermal layers of six slides (®ve visual ®elds, magni®cation 3 40) were
counted; mean and standard deviation values were calculated. The
signi®cance level of given differences was determined using the c2-test.
BrdU incorporation BrdU (3.5 mg; Sigma) was dissolved in 750 ml
sodium chloride and injected intraperitoneally, 1 h before the mice were
killed by cervical dislocation. Biopsies were taken from the four
experimental sites and an untreated control area of each animal. BrdU
incorporation into the nuclei of keratinocytes was visualized using the
alkaline phosphatase anti-alkaline phosphatase method (Universal APAAP
Kit mouse, Dakopatts system 40, Dako Diagnostika, Hamburg,
Germany). Brie¯y, the slides were covered with 10% normal rabbit
serum (30 min) and then incubated with the primary antibody (aBrdU
from mice, Amersham RPN 202, Amersham-Buchler, Braunschweig,
Germany) for 1 h, before being cleared with Tris buffer for 15 min. The
slides were then incubated with a second antibody (rabbit anti-mouse
IgG) for 1 h, cleared with Tris buffer 15 min, incubated with the
immune complex (alkaline phosphatase anti-alkaline phosphatase) for 1 h
and then cleared with Tris buffer for 15 min. The slides were incubated
with substrate for 20 min, cleared with Tris for 5 min and then washed
with distilled water for 1 min and lukewarm tap water for 10 min.
Counter-staining was performed with hematoxylin Mayer for 15 s. After
a ®nal wash with distilled water for 1 min the specimens were covered
with a mounting medium (Dako Glycergel Mounting Medium S63,
Dako). The BrdU-incorporated nuclei appeared brilliant red in this stain.
The proliferating basal keratinocytes were counted in six slides under a
microscope (3 40), mean value and standard deviation were calculated,
and the signi®cance level of given differences was determined using the
c2-test. The index of proliferation was calculated by dividing the average
of the counted proliferating cells per six high-power ®eld by the average
of the proliferating cells by the control slides from untreated sites.
RESULTS
HLE stimulates hyperproliferation of keratinocytes
in vitro HLE signi®cantly increased BrdU uptake by keratino-
cytes in a concentration-dependent manner (Fig 1). Already a
concentration of 0.3 nM HLE induced proliferation signi®cantly.
A maximum increase was observed at 3.3 nM reaching a plateau at
10 nM HLE. Higher concentrations of HLE resulted in a partial to
complete detachment of the cells. The increase in proliferation was
comparable with that observed following stimulation with human
epidermal growth factor (100 nM). Applying HLE together with
elastase inhibitors, ela®n and anti-leukoprotease, abolished HLE-
induced proliferation completely. The inhibitors had no in¯uence
on BrdU incorporation by keratinocytes.
HLE induces hyperproliferation in vivo Topical application of
HLE on hairless mice under occlusion resulted in a pronounced
induction of proliferation as well as epidermal thickness after 72 h.
Hematoxylin and eosin stained biopsies showed marked
Figure 1. HLE-induced proliferation in murine keratinocytes.
Proliferation was measured by incorporation of BrdU in the murine
keratinocyte cell line PAM-212 using a cell proliferating enzyme-linked
immunosorbent assay. Cells were treated with HLE (0.1±33 nM) for
24 h. Concentration of 33 nM led to » 50% detachment of cells (#).
Increase of proliferation depended on proteolytic activity as shown by
adding HLE (10 nM) preincubated with ela®n (100 nM) or anti-
leukoprotease (100 nM). Values are mean 6 SD of six separate
experiments performed in duplicate. Signi®cant difference compared
with medium control: *p < 0.001.
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vasodilatation but no signi®cant in¯ammatory in®ltrate. HLE-
treated sites developed a visible stratum granulosum and showed a
curved dermoepidermal junction, suggesting the initial
development of a papilla-like folding of the dermis (Fig 2).
Breaking the barrier once with acetone followed by application of
the buffers under occlusion did not result in any signi®cant signs of
in¯ammation and no induction of epidermal hyperproliferation or
increase of epidermal thickness after 72 h (Table I).
The HLE-induced hyperproliferation showed a strong dose±
response relationship in regard to the number of proliferating
keratinocytes (Fig 3A) and increase of epidermal keratinocyte
layers (Fig 3B). Already a minimal dose of 0.043 pmol HLE per
cm2 skin increased the proliferation of keratinocytes and thickened
the epidermis. Application of HLE (434.8 pmol per cm2 skin)
increased the number of proliferating basal keratinocytes 5-fold,
whereas the thickness of the epidermis doubled. After a period of
24 h following the application of HLE (0.43 pmol per cm2 skin) an
erythema was observed. This became more pronounced with
increasing concentration of HLE up to 434 pmol per cm2
(Table I). Comparable effects were observed following the
application of porcine pancreas elastase. A signi®cant increase in
proliferation (proliferation index 1.7 6 0.6, n = 6) and a resultant
thickening of the epidermis (5.3 6 0.6) was achieved using a
concentration of 3 pmol pancreas elastase per cm2 skin. The
maximum concentration of 300 pmol pancreas elastase per cm2
skin augmented the proliferation index nearly 4-fold and thickened
the epidermis from 3.2 6 0.2 to 5.1 6 0.7 epidermal layers.
Application of the buffers and more pronounced application of
leukocyte and pancreatic elastase resulted in an increase in TEWL
3 d after treatment (Table I). An erythema was visible 24 h after
treatment with 30 pmol pancreas elastase per cm2 skin.
Effect of protease inhibitors Applying HLE together with a
molar excess of the physiologic inhibitors ela®n, anti-
leukoprotease, and a1-proteinase inhibitor abolished the HLE-
induced hyperproliferation completely (Fig 4). In contrast, the
addition of a vast molar excess of inhibitors for trypsin-like enzymes
(1 mM n-p-tosyl-l-lysine chloromethyl ketone) as well as for
chymotrypsin-like enzymes (1 mM n-tosyl-l-phenylalanine
chloromethyl ketone) did not in¯uence the hyperproliferative
effect of HLE (data not shown).
DISCUSSION
Several cytokines and growth factors are able to modulate
keratinocyte proliferation and have been studied in subcon¯uent
keratinocyte cultures. Interleukin-1 (Ristow, 1987), interleukin-3
(Hancock et al, 1988), interleukin-6 (Grossman et al, 1989),
interleukin-8 (Tuschil et al, 1992), transforming growth factor-a
(Coffey et al, 1987), epidermal growth factor (Carpenter and
Cohen, 1979), and granulocyte-macrophage colony stimulating
factor (Hancock et al, 1988) have been shown to increase
proliferation. Tumor necrosis factor-a (Kono et al, 1990), inter-
feron-a (Nickoloff et al, 1984), interferon-b (Nickoloff et al, 1989),
and transforming growth factor-b (Hsuan, 1989) are known to
inhibit the proliferation of keratinocytes. There is no proof that
these stimuli are able to induce the proliferation of keratinocytes in
viable skin. Therefore we were interested, whether HLE is capable
of inducing pronounced keratinocyte proliferation both in vitro and
in vivo.
In vitro HLE induced proliferation in the murine keratinocyte
cell line PAM-212. The HLE-mediated proliferative response of
keratinocytes was dependent on the enzymatic activity of HLE at
concentrations from 1 to 30 nM. Application of HLE together with
Figure 2. HLE induced epidermal hyper-
proliferation within 3 d. Histologic sections
of buffer-treated (A) and HLE-treated (434.8
pmol per cm2) skin (B). BrdU incorporation
(C) after application of HLE-treated (34 pmol
per cm2) skin. In HLE-treated skin no
signi®cant in¯ammatory in®ltrate was visible.
Bars: 200 mm.
Table I. TEWL, proliferating keratinocytes, epidermal thickness, and erythema after 3 d of elastase applicationa
TEWL 0 h
ppm
TEWL 72 h
%
Proliferation
Index
Keratinocyte
layers
Erythema
24 h
Untreated sites 40b ± 1 2.6 6 0.2 0
(30±60)
Buffer control 491 13 (11±15) 1 3.2 6 0.2 0
(390±600)
Leukocyte elastase 506 22 (17±26) 5.0 6 0.9 5.0 6 0.7 ++
(380±600)
Pancreatic elastase 524 18 (17±19) 3.9 6 1.4 5.1 6 0.7 ++
(405±610)
aThe lipids from the skin of hairless mice were removed by acetone pretreatment. Afterwards phosphate-buffered saline (buffer), HLE (434 pmol per cm 2skin), and por-
cine pancreatic elastase (300 pmol per cm 2skin) were applied daily under occlusion for 72 h (n = 6). The TEWL was determined after acetone treatment (TEWL 0 h) and
after 3 d (TEWL 72 h in % of TEWL 0 h). The number of proliferating keratinocytes (BrdU-positive keratinocytes/6 high-power ®eld) was given as a factor of the un-
treated sites (proliferation index). The average number of keratinocyte layers of 6 high-power ®eld was determined for each test-site.
bWithout acetone pretreatment. Data are expressed as mean 6 SD (n = 6). Erythema was graded subjectively as absent (0), slight (+/±), moderate (+), and pronounced
(++).
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a molar excess of the human keratinocyte-derived protease
inhibitors ela®n (Wiedow et al, 1990) and antileukoprotease
(Wiedow et al, 1993) inhibited the proliferative effect. The
concentrations of HLE that induced signi®cant proliferation in
cultured keratinocytes were similar to those seen in investigations
with other serine-proteases such as thrombin, trypsin, or mast cell
tryptase to activate PAR on keratinocytes. Concentrations of
thrombin from 10 pM to 10 nM induced keratinocytes prolifer-
ation by activation of PAR-1 (Derian et al, 1997; Algermissen et al,
2000). It has been demonstrated that activation of PAR-2 by
20 nM trypsin, 60 nM mast cell tryptase or the PAR-2 activating
peptide SLIGRL resulted in decreased keratinocyte proliferation
(Derian et al, 1997; Algermissen et al, 1999); however, it has also
been reported that mast cell tryptase is capable of inducing
keratinocyte proliferation (Pohlig et al, 1996). In lung ®broblasts
activation of PAR-2 by 5±20 nM trypsin or 2±70 mU tryptase per
ml exhibited proliferative effects (Akers et al, 2000) implicating a
cell type speci®c effect of PAR-2-activation on cell proliferation.
To the best of our knowledge a receptor-mediated response to
HLE in keratinocytes has not been proposed yet. Loew et al (2000)
showed that HLE abolished activation of PAR-1 and decreased the
PAR-2 activity in endothelial cells. None of the PAR-1±4 has
been shown to be activated by HLE.
Topical application of HLE on viable murine skin induced
epidermal hyperproliferation. Histologic analysis revealed marked
vasodilatation but no in¯ammatory in®ltrate. This points towards a
direct proliferative effect of HLE on keratinocytes. Signi®cant
proliferation of basal keratinocytes with a concomitant signi®cant
increase of epidermal layers could be achieved with 43 fmol HLE
per cm2 skin (applied concentration 4.3 nM). The maximum
increase in epidermal thickness was reached with 4.3 pmol per cm2
skin (applied concentration 430 nM). Concentrations of HLE
necessary for the induction of hyperproliferation in vitro were
approximately 10 times less. This might be explained by the fact
that HLE applied at the skin surface had to diffuse down to basal
keratinocytes, which will be accompanied by a loss of activity.
Application of HLE together with a molar excess of the protease
inhibitors, antileukoprotease and ela®n, inhibited the proliferative
effect almost completely. The same effect was observed with
application of HLE together with human a1-proteinase inhibitor
(53 kDa). We conceive that the inhibition is caused by inhibiting
the proteolytic activity and not to a reduced penetration due to the
larger molecular weights of enzyme-inhibitor complexes because
the application of enzyme and inhibitor resulted in unchanged
proliferation both in vitro and in vivo. Moreover, a complex of the
reversible inhibitor ela®n (6 kDa) and elastase (30 kDa) with a total
weight of 36 kDa might have an in¯uence on the penetration. As
HLE and pancreatic elastase induced epidermal proliferation in this
Figure 3. Effects of HLE on the proliferation of keratinocytes
and the thickening of the epidermis. (A) Keratinocytes; (B)
epidermis. The cells that incorporated BrdU per basal membrane length
(A) and the epidermal keratinocyte layers were counted. n = 12,
controls: n = 30 (A) and n = 42 (B), *p < 0.001.
Figure 4. HLE induced epidermis proliferation in the presence of
physiologic inhibitors. HLE-treated (434.8 pmol per cm2) skin was
compared with HLE + equimolar concentrations of ela®n, anti-
leukoprotease, and a1-proteinase inhibitor. The TEWL (A), the index of
proliferation (B), and the number of epidermal layers (C ) were
determined. n = 6, *p < 0.001.
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study the question occurs whether the same ®ndings would have
been obtained with other proteolytic enzymes. Controls with
pancreatic trypsin and chymotrypsin resulted also in pronounced
epidermal proliferation (data not shown). The biologic meaning
remains unclear as these enzymes do not occur to our knowledge in
human epidermis. Whether epidermis derived proteases such as
stratum corneum chymotryptic enzyme and stratum corneum
tryptic enzyme, which exhibit trypsin-like and chymotrypsin-like
activity, are able to cause epidermal hyperproliferation has not been
investigated so far.
The concentrations of HLE, which were tested on hairless mice
and cultured keratinocytes in this study, are comparable with those
found on the skin surface of psoriatic lesions (Wiedow et al, 1995).
Measuring the skin surface proteolytic activity of HLE on psoriatic
lesions the 95% con®dence interval was between 5 and 50 fmol
HLE per cm2 skin the range between 0.5 fmol and 40 pmol HLE
per cm2 skin. The high variation re¯ects the variability of the
neutrophil in®ltrate in psoriatic lesions. Elastase might be an
important stimulus for epidermal proliferation in early stage
psoriasis as HLE was detected predominantly in acute lesions
(Glinski et al, 1984). It is believed that psoriatic lesions enlarge by
centrifugal expansion (Ragaz and Ackerman, 1979; Gerritsen et al,
1997). The margin of spreading plaques represents the most active
site, as indicated by a higher density of spongiform pustules of
Kogoj and microabscesses of Munro (Beurskens et al, 1989; Van de
Kerkhof and Chang, 1989). Studies that demonstrated that ela®n is
increased within the psoriatic plaque (Schalkwijk et al, 1993) and
signi®cantly more in the region of the center than in the margin
(Van de Kerkhof et al, 1991) provide evidence that elastase may also
be a crucial factor for the enlargement of psoriatic plaques.
Quanti®cation of epidermal cell populations in the center and
margin of stable psoriatic plaques, which had not spread the last
2 wk, exhibited no signi®cant changes for in¯ammation and
proliferation with a great heterogeneity (Mommers et al, 1999).
Further quantitative studies are needed to substantiate the differ-
ences between the margin and the center of spreading psoriatic
plaques and if the release of HLE is involved in this process.
It is conceivable that proteolytic enzymes such as serine
proteases are important stimuli for the induction of keratinocyte
hyperproliferation. It has been shown that the hyperproliferation
of human skin induced by minimal trauma such as removal of
horny layers by tape stripping is suppressed by trypsin inhibitors
(Denda et al, 1997). In morphologic investigations on human
epidermal sheets by electron microscopy, structural changes of
keratinocytes in response to HLE such as mitochondrial
swelling, intracytoplasmatic lipid inclusions, and building of
microtubuli were detected (Ludolph-Hauser et al, 1999). HLE
has been shown to detach cultured keratinocytes and to degrade
hemidesmosomes and components of the basal membrane in
biopsies of human skin (Briggaman et al, 1984; Heck et al,
1990; Glinski et al, 1991; Katayama et al, 1994). These changes
indicate that keratinocytes respond actively to HLE.
In summary, we were able to demonstrate that HLE can induce
hyperproliferation in keratinocytes both in vitro and in vivo. A
comparison between murine and human epidermis remains
speculative. The concentrations necessary for the hyperproliferative
response were similar to those observed in psoriatic lesions, whereas
the concentrations of cytokines and growth factors capable of
inducing keratinocyte proliferation are largely unknown in the
psoriatic epidermis. Experiments with human keratinocytes and
human epidermis are in progress to clarify the role of leukocyte
elastase as a driving force of keratinocyte proliferation in psoriatic
patients.
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